Celcuity (CELC) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.07

Estimate

-$1.08

Surprise

+0.9%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Celcuity (CELC) reported a narrower loss than forecast — diluted EPS of -$1.07 against the -$1.08 estimate (a 0.9% beat on a still-unprofitable quarter).

• HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target — benzinga, 2026-08-14
• Celcuity Analysts Slash Their Forecasts After Q2 Loss — benzinga, 2026-08-14
• Stifel Maintains Buy on Celcuity, Lowers Price Target to $150 — benzinga, 2026-08-14

TrendMatrix currently rates CELC Sell at 4.9/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +0.9% surprise compares with a +12.6% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$85.00

Price target

$140.15

Stop

$80.55

Upside to target

+64.9%

Reward-to-risk

7.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$4.08B

P/E (fwd)

-1043.1

52-week range

$44.42–$151.02

Off 52-week high

43.7%

RSI (14)

35

Volume vs avg

1.09×

Score today

4.9/10